Dedicated to Discovery. Committed to Care.

Office of Research and Technology Ventures

Licensing

Licensing Policies

breast cancer cell

Dana-Farber licenses its technology to enable the development of new products and services. Ideal licensing partners will:

  • possess the resources and commitment necessary to develop and commercialize Dana-Farber technology;
  • provide Dana-Farber with fair consideration in exchange for the license.
Common elements of license agreements with Dana-Farber:
  • Grant of Rights
    Dana-Farber will offer an exclusive or non-exclusive license depending on the nature of the technology
  • Retained Rights
    As a non-profit research institution, Dana-Farber retains the following rights to:
    • use the technology for teaching, research and education;
    • grant non-exclusive research use licenses to other academic and non-profit organizations for non-commercial purposes.
  • Financial Terms
    Financial terms may include upfront license fees, equity, milestone payments, annual minimum royalties or maintenance fees or running royalties.
  • Patent Reimbursement
    Dana-Farber will typically expect licensees to reimburse incurred and ongoing patent expenses related to the licensed technology.
  • Diligence Requirements
    The license agreement will be structured to include diligence provisions that provide Dana-Farber with tangible evidence that the licensee is diligently developing and commercializing the licensed technology.
  • Indemnification, insurance and product liability
    Licensees are required to indemnify Dana-Farber against liabilities and claims related to product development and sales. Prior to the first commercial sale of a product developed using Dana-Farber technology, licensees are required to obtain product liability insurance.

For a detailed description of relevant policies, please see Dana-Farber's Research Policy and Procedure Manual.